PURINE METABOLISM AND MICROALBUMINURIA IN PATIENTS WITH METABOLIC SYNDROME
Keywords:
metabolic syndrome, hyperuricemia, microalbuminuria, arterial hypertension, insulin resistanceAbstract
The aim of this work was to study the state of purine metabolism and microalbuminuria in patients with metabolic syndrome. We examined 50 patients aged 30-55 years, who were randomized into 3 groups: I (control) – healthy individuals t – 15 people, II – patients with arterial hypertension – 18 people, group III – patients with arterial hypertension in combination with metabolic syndrome – 32 people. The results of the studies showed that the concentration of UA in the blood significantly correlated with the severity of obesity, hyperinsulinemia, triglyceridemia and glycemia - parameters that reflect the state of IR. Thus, the data obtained indicate that hyperuricemia is a metabolic disorder and one of the components inherent in the metabolic syndrome.
References
Abilova S.S. Noruzbaeva A.M., Lunegova A.M., Mirrakhimov E.M. The significance of metabolic syndrome in clinical practice. // Central Asian Medical Journal. 2014 Volume X, No. 6, pp. 316-323.
Alavi A.L., Tulyaganova D.K., Babaev M.A., Shodiev J.D. Dynamics of indicators of platelet homeostasis of lipid metabolism in patients with metabolic syndrome on the background of drug therapy. // Res. Scientific and practical. The conference. 2008. pp.30-31.
Janashia P.H., Didenko V.A. Is hyperuricemia a component of metabolic syndrome? // Ross. Cardiological Journal No. 1. 2011 pp. 1-9
Donskov A.S., Balkarov I.M., Dadina Z.M., et al. Urate kidney damage and metabolic shifts in patients with arterial hypertension. Ter. archive. 1999; 6: Pp. 53-56.
Kobalova Zh.D., Tolkacheva V.V., Karaulova Yu.L. Uric acid is a marker and/or a new risk factor for the development of cardiovascular complications. Rus med journal 2012; 10: Pp. 431-436.
Mavlyanov I.R., Spiridonova A.Y. Metabolic syndrome and kidneys. The first Tashkent state University. Institute. Journal SHARHLAR, 2004, Pp. 27-40.
Mammadov M.N., Petrova N.V., Metelskaya V.A., etc. Components of the metabolic syndrome in patients with arterial hypertension. Cardiology; 12: Pp. 37-41.
8. Tashkent, E.N. Hyperuricemia in the mechanisms of development of metabolic syndrome and cardiovascular complications. Med. Uz-bekistan Journal 2006, No. 4 Pp. 91-95
Bleyer A.J. et al. Renal manifest factions of a mutation in the uromodium (Tamm Horsfall protein) gene. Amer J kidney Dis. 2013;42: P20-26.
De Leeuw, Birkenhager W.H. Kidney damage in hypertension and the effects of treatment. Neth J. Med. 2009; 47: P 199-204.
Effects of ramipril on cardiovascular and microvascular outcome in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2015; 355: P 253.
Filer .IS Lent in resistance and obesity: Pre¬sented at the.60 th scientific ses-sions of the American diabetes association. June 13, 2016; San-Antonio, Texas.
Ford E.S., Ciles W.H., Dietr W.H. Prevalence of the metabolic syndrome amond US adults. JAMA 2012; 287: P.356-359.
Lakka HM. Laaksonen DE. Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 2012; 288: P 2709-2716.
Malik F.S., Lavie C.J., Mehra M.R. et al. Renin-angiotensin system; Genes to bedside. Amer Heart J. 2015; 134: P 514-526
